A comprehensive review of 24 randomized clinical trials involving 12,661 adults with plaque psoriasis suggests that interclass switching of biologic drugs leads to superior treatment outcomes without heightened safety risks compared to remaining on the same therapy. Significant improvements in Psoriasis Area and Severity Index (PASI) scores were noted as early as four weeks post-switch. Notably, transitioning from TNF-α inhibitors to IL-23p19 inhibitors yielded the greatest skin clearance. However, researchers highlighted the necessity of monitoring for infections during these therapy changes.

Source: JAMA Dermatology